Questions about the clinical significance of improvements to medication adherence resulting from value-based insurance design (VBID) policies persist in the literature. Given the lack of conclusive evidence about effectiveness, in addition to concerns about the cost of implementing VBID programs, it is perhaps not surprising that VBID is not more widely used by managed care plans. Although VBID holds promise for improving chronic medication use, additional evidence is needed if VBID is to become universally adopted. DISCLOSURES: No funding contributed to the writing of this article. The author currently receives funding from Blue-Cross Blue-Shield of Minnesota for unrelated research.
|Original language||English (US)|
|Number of pages||3|
|Journal||Journal of Managed Care and Specialty Pharmacy|
|State||Published - Jul 1 2019|
Bibliographical noteFunding Information:
No funding contributed to the writing of this article. The author currently receives funding from Blue-Cross Blue-Shield of Minnesota for unrelated research.
Copyright © 2019, Academy of Managed Care Pharmacy. All rights reserved.
- Managed Care Programs/economics
- Medication Adherence/statistics & numerical data
- Value-Based Health Insurance/economics
PubMed: MeSH publication types
- Journal Article